摘要
ROS1融合基因是非小细胞肺癌(non-small cell lung cancer,NSCLC)靶向治疗的又一潜力靶点,随着相应靶向药物的使用,ROS1阳性的NSCLC患者生存期明显改善。越来越多针对ROS1融合基因的治疗药物面世,让这类患者有更多的选择。但持续性用药后的获得性耐药问题仍无法避免。本文就ROS1融合基因的检测方法、靶向治疗情况及耐药的机制和策略进行综述。
ROS1 fusion gene is a potential target of targeted therapy for non-small cell lung cancer(NSCLC).With the use of targeted drugs,the survival of ROS1-positive NSCLC patients has been significantly improved.More and more drugs targeting ROS1 fusion gene have been developed,providing more choices for such patients.However,the problem of acquired drug resistance after persistent drug use is still unavoidable.The review has summarized the methods of ROS1 fusion gene detection,targeted therapy and drug resistance mechanisms and strategies.
作者
张瑞锋
张奇
刘林林
ZHANG Ruifeng;ZHANG Qi;LIU Linlin(Department of Radiation Oncology,the Second Affiliated Hospital of Jilin University,Jilin Changchun 130041,China)
出处
《现代肿瘤医学》
CAS
北大核心
2021年第21期3851-3854,共4页
Journal of Modern Oncology
基金
国家自然科学基金(编号:81773523)
吉林省科技厅项目(编号:20190101020JH)。
关键词
非小细胞肺癌
ROS1融合基因
基因检测
靶向治疗
耐药
non-small-cell lung cancer
ROS1 fusion gene
genetic testing
targeted therapy
drug resistance
